This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT03213652

Conditions

1. Hematopoietic and Lymphoid Cell Neoplasm
2. Malignant Solid Neoplasm
3. Recurrent Ependymoma
4. Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
5. Recurrent Hepatoblastoma
6. Recurrent Langerhans Cell Histiocytosis
7. Recurrent Malignant Germ Cell Tumor
8. Recurrent Malignant Glioma
9. Recurrent Medulloblastoma
10. Recurrent Neuroblastoma
11. Recurrent Non-Hodgkin Lymphoma
12. Recurrent Osteosarcoma
13. Recurrent Rhabdomyosarcoma
14. Recurrent Soft Tissue Sarcoma
15. Recurrent WHO Grade II Glioma
16. Refractory Ependymoma
17. Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
18. Refractory Hepatoblastoma
19. Refractory Langerhans Cell Histiocytosis
20. Refractory Malignant Germ Cell Tumor
21. Refractory Malignant Glioma
22. Refractory Medulloblastoma
23. Refractory Neuroblastoma
24. Refractory Non-Hodgkin Lymphoma
25. Refractory Osteosarcoma
26. Refractory Rhabdomyosarcoma
27. Refractory Soft Tissue Sarcoma
28. Wilms Tumor

Interventions

1. Drug: Ensartinib
2. Other: Laboratory Biomarker Analysis
3. Other: Pharmacological Study

MeSH:Lymphoma Neoplasms Sarcoma Lymphoma, Non-Hodgkin Glioma Neuroblastoma Neoplasms, Germ Cell and Embryonal Osteosarcoma Rhabdomyosarcoma Ependymoma Sarcoma, Ewing Medulloblastoma Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Wilms Tumor Neuroectodermal Tumors, Primitive, Peripheral Hepatoblastoma Histiocytosis, Langerhans-Cell Histiocytosis

HPO:Embryonal neoplasm Ependymoblastoma Ependymoma Ewing sarcoma Glioma Hepatoblastoma Histiocytosis Lymphoma Medulloblastoma Medulloepithelioma Neoplasm Nephroblastoma Neuroblastoma Neuroectodermal neoplasm Non-Hodgkin lymphoma Osteosarcoma Peripheral primitive neuroectodermal neoplasm Primitive neuroectodermal tumor Rhabdomyosarcoma Sarcoma Soft tissue sarcoma

EXPLORATORY OBJECTIVES: I. To evaluate other biomarkers as predictors of response to ensartinib and specifically, whether tumors that harbor different missense mutations or fusions (including the crizotinib resistant F1174L ALK variant) will demonstrate differential response to ensartinib treatment. --- F1174L ---